Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - yellow fever virus -

Bandaríkin - enska - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - telmisartan (unii: u5syw473rq) (telmisartan - unii:u5syw473rq) - telmisartan 20 mg - telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety o

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

marine nature pharmaceuticals australia pty ltd - zinc gluconate, quantity: 55.75 mg (equivalent: zinc, qty 8 mg); pyridoxine hydrochloride, quantity: 25 mg (equivalent: pyridoxine, qty 20.5 mg); undaria pinnatifida, quantity: 117.65 mg (equivalent: undaria pinnatifida, qty 1.411 g); magnesium citrate, quantity: 154.33 mg (equivalent: magnesium, qty 25 mg); ascorbic acid, quantity: 50 mg - capsule, hard - excipient ingredients: calcium hydrogen phosphate dihydrate; purified water; microcrystalline cellulose; colloidal anhydrous silica; hypromellose; magnesium stearate - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; helps maintain/support healthy acid/alkali balance in the body ; maintain/support general health and wellbeing ; maintain/support connective tissue health ; aid/assist/helps connective tissue production/formation ; aid/assist healthy red blood cell production ; maintain/support blood capillary health ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support immune system to fight illness ; maintain/support nervous system health ; maintain/support nervous system function ; maintain/support skin health ; maintain/support wound healing

Bandaríkin - enska - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y) - milprosa™ is indicated to support embryo implantation and early pregnancy (up to 10 weeks post-embryo transfer) by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women up to and including 34 years of age. limitation of use efficacy in women 35 years of age and older has not been established. milprosa is contraindicated in women with: - known sensitivity to progesterone or any of the ingredients of milprosa [see description (11)] - undiagnosed vaginal bleeding - severe hepatic impairment or disease - known or suspected malignancy of the breast - active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events risk summary milprosa is indicated to support embryo implantation and early pregnancy as part of an assisted reproductive technology treatment program in vitro fertilization (ivf) with or without intracytoplasmic sperm injection (icsi) and embryo transfer for infertile women. maternal risks a

Bandaríkin - enska - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 40 mg - diovan® is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with diovan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint nation

Bandaríkin - enska - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - valsartan 80 mg - diovan hct (valsartan and hydrochlorothiazide, usp) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the angiotensin ii receptor blocker (arb) class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with diovan hct. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education

Bandaríkin - enska - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - amlodipine 5 mg - exforge (amlodipine and valsartan) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine and the angiotensin ii receptor blocker (arb) class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with exforge. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national com

Bandaríkin - enska - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - amlodipine 5 mg - exforge hct (amlodipine, valsartan, and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the angiotensin ii receptor blocker (arb) class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with exforge hct. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high b

Írland - enska - HPRA (Health Products Regulatory Authority)

zaphyr pharmaceuticals ireland limited - anastrozole - film-coated tablet - 1 milligram(s) - aromatase inhibitors; anastrozole

Bandaríkin - enska - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - deferoxamine mesylate (unii: v9tko7eo6k) (deferoxamine - unii:j06y7mxw4d) - deferoxamine mesylate 500 mg - desferal is indicated as an adjunct to standard measures for the treatment of acute iron intoxication. desferal is indicated for the treatment of transfusional iron overload in patients with chronic anemia. desferal is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). desferal is contraindicated in patients with: - a history of a hypersensitivity reaction to deferoxamine or any of its inactive ingredients [see description (11)] . reactions have included anaphylaxis [see warnings and precautions (5.1)] . - severe renal disease or anuria since the drug and the iron chelate are excreted primarily by the kidney [see warnings and precautions (5.3)] . risk summary there are no available data on desferal use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriages or adverse maternal or fetal outcomes. in animal reproduction studies subcutaneous administration of deferoxamine to pregnan